As Celgene Corp (CELG) Stock Price Declined, Cannell Peter B & Company INC Has Upped by $6.95 Million Its Position

May 27, 2018 - By Migdalia James

Celgene Corporation (NASDAQ:CELG) LogoInvestors sentiment decreased to 0.83 in 2017 Q4. Its down 0.34, from 1.17 in 2017Q3. It is negative, as 156 investors sold CELG shares while 478 reduced holdings. 118 funds opened positions while 411 raised stakes. 561.38 million shares or 7.06% less from 603.99 million shares in 2017Q3 were reported. Great Lakes Advisors Lc owns 3,642 shares. Syntal Prtn Limited Liability Com accumulated 0.12% or 3,900 shares. Skylands Capital Ltd Llc owns 80,410 shares for 1.08% of their portfolio. Sun Life has 1,722 shares for 0.02% of their portfolio. Jump Trading Llc holds 0.04% of its portfolio in Celgene Corporation (NASDAQ:CELG) for 3,217 shares. Gp One Trading Limited Partnership stated it has 0.09% of its portfolio in Celgene Corporation (NASDAQ:CELG). Logan Capital Mgmt, Pennsylvania-based fund reported 99,129 shares. Adell Harriman & Carpenter has 0.49% invested in Celgene Corporation (NASDAQ:CELG). Guardian Life Ins Co Of America has 0.06% invested in Celgene Corporation (NASDAQ:CELG). Martin Mngmt Limited Liability invested in 4.51% or 110,716 shares. Community Savings Bank Na invested in 4,360 shares or 0.05% of the stock. Comm Bank & Trust reported 0.23% in Celgene Corporation (NASDAQ:CELG). Affinity Investment Advisors Lc holds 0.96% or 81,363 shares in its portfolio. Zurcher Kantonalbank (Zurich Cantonalbank) invested in 0.32% or 342,640 shares. Glg Prtn LP holds 9,290 shares or 0.05% of its portfolio.

Since February 8, 2018, it had 2 insider purchases, and 3 insider sales for $3.48 million activity. MARIO ERNEST sold $1.26 million worth of stock. KAPLAN GILLA sold $1.77M worth of stock or 18,500 shares. LOUGHLIN JAMES J sold 9,250 shares worth $851,093.

J. Carlo Cannell increased its stake in Celgene Corp (CELG) by 4.42% based on its latest 2017Q4 regulatory filing with the SEC. Cannell Peter B & Company Inc bought 66,820 shares as the company’s stock declined 19.30% with the market. The hedge fund run by J. Carlo Cannell held 1.58 million shares of the major pharmaceuticals company at the end of 2017Q4, valued at $164.82M, up from 1.51 million at the end of the previous reported quarter. Cannell Peter B & Company Inc who had been investing in Celgene Corp for a number of months, seems to be bullish on the $57.11B market cap company. The stock decreased 1.14% or $0.91 during the last trading session, reaching $78.63. About 4.78 million shares traded. Celgene Corporation (NASDAQ:CELG) has declined 31.28% since May 27, 2017 and is downtrending. It has underperformed by 42.83% the S&P500.

Cannell Peter B & Company Inc, which manages about $3.77 billion and $2.91B US Long portfolio, decreased its stake in Hd Supply Holdings Inc (NASDAQ:HDS) by 120,097 shares to 1.78 million shares, valued at $71.18M in 2017Q4, according to the filing. It also reduced its holding in Ball Corp (NYSE:BLL) by 292,493 shares in the quarter, leaving it with 499,027 shares, and cut its stake in Amerigas Partners Lp (NYSE:APU).

More notable recent Celgene Corporation (NASDAQ:CELG) news were published by: which released: “Generic Revlimid Could Sink Celgene” on May 16, 2018, also with their article: “Celgene Earnings Preview” published on April 30, 2018, published: “Celgene’s (CELG) Management Presents at Bank of America Merrill Lynch Healthcare Conference (Transcript)” on May 16, 2018. More interesting news about Celgene Corporation (NASDAQ:CELG) were released by: and their article: “5 Top Stock Trades for Tuesday Morning” published on May 22, 2018 as well as‘s news article titled: “Celgene And Otezla Are Cracking” with publication date: May 14, 2018.

Celgene Corporation (NASDAQ:CELG) Ratings Coverage

Among 22 analysts covering Celgene (NASDAQ:CELG), 15 have Buy rating, 0 Sell and 7 Hold. Therefore 68% are positive. Celgene had 38 analyst reports since December 8, 2017 according to SRatingsIntel. The stock has “Buy” rating by Leerink Swann on Monday, May 7. Stifel Nicolaus maintained Celgene Corporation (NASDAQ:CELG) on Monday, January 8 with “Buy” rating. The firm has “Buy” rating given on Monday, February 5 by Mizuho. The stock has “Buy” rating by RBC Capital Markets on Wednesday, April 4. The firm has “Buy” rating by BMO Capital Markets given on Monday, January 8. The firm earned “Hold” rating on Wednesday, February 28 by SunTrust. On Friday, January 5 the stock rating was downgraded by Bank of America to “Hold”. The company was maintained on Wednesday, March 21 by JP Morgan. The firm has “Buy” rating by Oppenheimer given on Friday, May 25. The firm earned “Hold” rating on Thursday, January 25 by Piper Jaffray.

Celgene Corporation (NASDAQ:CELG) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.